Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
R&D Licensing
Filter     Order     Display # 
Date Item Title
09 Mar 2006 Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UMN Pharma
08 Mar 2006 Emisphere Announces Oral PTH License Agreement
08 Mar 2006 Diabetica Announces A Development Licence For Gip Agonist Antidiabetic Therapeutics
08 Mar 2006 Connetics Licenses Technology for the Treatment of Hyperhidrosis
07 Mar 2006 Antisoma to evaluate rainforest anti-cancer compounds from EcoBiotics Ltd
07 Mar 2006 SurModics Gains Access to Biodegradable Polymer Technology for Site Specific Drug Delivery from InnoCore
07 Mar 2006 GlaxoSmithKline and Myogen Announce Pulmonary Arterial Hypertension Partnership; GlaxoSmithKline to Commercialize Ambrisentan in All Territories Outside of the U.S.
02 Mar 2006 Sangamo BioSciences Licenses MaxCyte Cell Loading Technology for ZFP Therapeutic Program for HIV/Aids
02 Mar 2006 Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development
02 Mar 2006 NicOx signs major new agreement with Pfizer for NOdonating compounds in ophthalmology
01 Mar 2006 ImQuest Pharmaceuticals, Inc. Licenses Entire Series Of Anti-HIV Therapeutic Compounds From Samjin Pharmaceutical Co.
28 Feb 2006 Zenyth announces in-licensing agreement
28 Feb 2006 ViroPharma Licenses Rights to Develop Novel Therapeutic for Treatment of Clostridium Difficile-Associated Disease
27 Feb 2006 BioSante Pharmaceuticals Signs Option and License for its CaP Technology for Use in Aesthetic Medicine
24 Feb 2006 Kyowa Hakko Kogyo to Introduce Self-Injectable Drug for Treating Parkinson's Disease from Britannia Pharmaceuticals
23 Feb 2006 Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea
23 Feb 2006 AvidBiotics Obtains Exclusive, Worldwide License to UC-San Diego's Protein Scaffold Technology
22 Feb 2006 Cadence Pharmaceuticals Announces Acquisition of Second Phase III Product and $60.8 Million Financing
22 Feb 2006 Inspire Announces Development and License Agreement with Boehringer Ingelheim International for Intranasal Epinastine in the United States and Canada
21 Feb 2006 Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect® for the Treatment of Inflammatory Bowel Disease
21 Feb 2006 Inspire Announces Development and License Agreement with Boehringer Ingelheim International for Intranasal Epinastine in the United States and Canada
18 Feb 2006 CytoCore Announces the Licensing of a New Bio-Marker That Identifies Uterine Pre-Cancerous and Cancer Cells
17 Feb 2006 Announcement Regarding Execution of a License Agreement with Novartis for KRP-203
15 Feb 2006 Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc.
14 Feb 2006 BioWa and Aphton Announce Licensing of BioWa’s POTELLIGENT™ Technology
14 Feb 2006 Replidyne and Forest Laboratories announce Faropenem Medoxomil licensing agreement
14 Feb 2006 Genmab licenses angiogenesis targets from Bionomics
14 Feb 2006 Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders
13 Feb 2006 BioXell and Lay Line Genomics announce License Agreement for Anti-TrkA Antibody against Pain
13 Feb 2006 Affymax and Takeda Announce Agreement To Develop and Commercialize Hematide™ in Japan
11 Feb 2006 Immtech licenses class of next generation anti-malarial drug candidates from Tulane University
08 Feb 2006 Centers for Disease Control and Prevention (CDC) and Ceragenix Enter into a Cooperative Research and Development Agreement (CRADA)
08 Feb 2006 MNLpharma announces exclusive licence agreement with Avexa to develop New Compounds to treat HIV/AIDS
08 Feb 2006 Oscient Pharmaceuticals Acquires Expanded Worldwide Rights to Lead Clinical Candidate Ramoplanin; Key milestone for commencing Phase III program
08 Feb 2006 G2 Therapies and Novo Nordisk announce global research, development and license agreement to develop and commercialise anti-inflammatory therapies
08 Feb 2006 Aphton to Expand Licensing and Commercialization
03 Feb 2006 AtheroGenics Extends Research and Development Collaboration with Astellas Pharma Inc.
03 Feb 2006 New Innovative Drugs to Treat Mitochondrial Diseases Exclusively Licensed to Samaritan
03 Feb 2006 Biocryst and Mundipharma international holdings limited collaborate on development of Fodosine™
03 Feb 2006 Amorfix Life Sciences Ltd. in-licenses novel technology to begin therapeutic program for neurodegenerative diseases
02 Feb 2006 Altea Therapeutics and Teikoku Seiyaku Co. Ltd. Enter into an Agreement for the Development, Manufacture, and Commercialization in Japan of a New Transdermal Therapy for Parkinson's Disease
01 Feb 2006 Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
01 Feb 2006 Medarex and Organon Announce Antibody Development Agreement
01 Feb 2006 Immusol announces an exclusive worldwide license agreement with Baylor College of Medicine for a novel cancer therapy.
01 Feb 2006 Isis Pharmaceuticals Licenses Proprietary Antibiotic Program to Achaogen
31 Jan 2006 CombinatoRx and Fovea Enter Into Collaboration to Develop Novel Ophthalmic Therapeutics Built from Synergistic Drug Combinations
31 Jan 2006 MediGene and Bradley Pharmaceuticals Enter Marketing and Development Partnership for Polyphenon® E* Ointment
31 Jan 2006 Methylgene and Pharmion announce North America, E.U. and international licensing agreement for oncology oral HDAC inhibitors, including Mgcd0103
30 Jan 2006 Medarex Receives Milestone Payment From ImClone Systems Following Acceptance of Investigational New Drug Application for Fully Human Antibody
30 Jan 2006 AtheroGenics and AstraZeneca Development and Commercialization Agreement for AGI-1067 Completes Early Hart-Scott-Rodino Review
 
<< Start < Prev 11 12 13 14 15 16 17 Next > End >>
Results 751 - 800 of 814

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics